Moderna: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 6, 2026, Moderna (NASDAQ:MRNA) announced an upgraded full-year revenue framework alongside positive Phase 3 clinical trial data for its individualized cancer therapy. The biotechnology company is demonstrating that its messenger RNA (mRNA) drug-delivery platform can expand beyond respiratory vaccines to high-value oncology treatments while controlling operating costs. Three key takeaways from management explain how this business transition affects long-term shareholders.

Moderna and partner Merck generated positive Phase 3 results for Intismeran autogene, an individualized neoantigen therapy (INT) designed to train a patient's immune system against specific tumor mutations. The clinical trial showed that adding the vaccine to Keytruda, an established immunotherapy, lowered relapse risks in skin cancer patients compared to Keytruda alone.

Management raised its 2026 full-year revenue growth target to between 15% and 25%, up from prior expectations of up to 10% growth. Expanded international supply agreements and stable domestic uptake for mNEXSPIKE, Moderna's updated COVID-19 vaccine, drove the outlook increase while cash spending dropped 10% year over year.

Continue reading